

1.	<p>Treatment & Condition</p> <p>Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura</p>
2.	<p>Associated appraisal body & Summary of ruling</p> <p>NICE Technology appraisal guidance (TA667), Published: 16 December 2020 www.nice.org.uk/guidance/ta667</p> <p>Caplacizumab with plasma exchange and immunosuppression is recommended, within its marketing authorisation, as an option for treating an acute episode of acquired thrombotic thrombocytopenic purpura (TTP) in adults, and in young people aged 12 years and over who weigh at least 40 kg. Treatment should be started and supervised by physicians experienced in managing thrombotic microangiopathies.</p> <p>It is recommended only if the company provides caplacizumab according to the commercial arrangement</p>
3.	<p>Number of people in Northern Ireland expected to take up service/therapy</p> <p>According to the Resource Impact Template that accompanies TA 667, NICE estimates in N.Ireland:</p> <ul style="list-style-type: none"> • 5 people having an acute episode of acquired TTP are eligible for treatment with caplacizumab each year
4.	<p>Patient Access Scheme Availability (Yes/No)</p> <p>The company (Sanofi Genzyme) has a commercial arrangement in place. This makes caplacizumab available to the NHS with a discount. The size of the discount is commercial in confidence.</p>
5.	<p>Infrastructure Requirements</p> <p>Any additional infrastructure costs associated will be dealt with as part of the routine commissioning process.</p>
6.	<p>Expected implementation period</p> <p>There is no impediment to immediate implementation for new patients.</p>
7.	<p>Commissioning arrangements</p> <p>This regimen will be formally commissioned by the HSCB/PHA via the Specialist Services Commissioning Team initially on a cost-per-case (CPC) basis. Thereafter, numbers of patients who received or are receiving treatment will be reviewed and consideration will be given to moving to recurrent funding to support this regimen.</p>
8.	<p>Monitoring arrangements</p> <p>The HSCB cost per case process will generate quarterly reports on the number of applications.</p>
9.	<p>DoH (NI) Legislative/Policy Caveats</p>

<p>This advice does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.</p>
--